ViaDerma engages Intent Sciences for Digital Marketing & Brand Development

ViaDerma, Inc.

ViaDerma, Inc.

INTENT SCIENCES has a proven track record of achieving exceptional outcomes with growing businesses of all types & sizes.

LOS ANGELES, Jan. 12, 2023 (GLOBE NEWSWIRE) —  ViaDerma, Inc., (OTC Pink: VDRM) is pleased to announce that they have engaged the growth marketing services of INTENT SCIENCES who will help grow the business online with brand development, go-to-marketing strategies, search engine optimization, social media, content marketing, and more this year.

INTENT SCIENCES has a proven track record of achieving exceptionally high growth results very cost-effectively for a wide range of companies around the world – from startups & small businesses to leading Fortune 500 brands across a variety of industries. Their digital marketing team is distributed and specializes in scaling up personalized digital marketing systems. This has helped to generate over $1 Billion in sales online for many brands. Learn more at their experience.

“We’re very honored and excited to be working with ViaDerma to help grow the brand and business online. Vitastem Ultra is an incredible first aid & antibiotic treatment that works miracles. The world really needs to know about the immense value Vitastem provides and we will be working very hard to make that happen,” said INTENT SCIENCES Founder & CEO, Michael Balducci.

The INTENT SCIENCES team will be working closely with ViaDerma management to help grow the B2B & DTC demand side for ViaDerma licensing and lead product Vitastem Ultra.

“The consumer demand is off the charts for the many ailments Vitastem is a great solution for. Primary data from Google indicates that Vitastem can be used to treat several skin diseases. There are 35 million searches each month in the US. From psoriasis, eczema, diabetic ulcers, acne scars, MRSA, and impetigo, to healing cuts & scrapes, surgical wounds, toenail fungus, first to third-degree burns, and pet wounds too. We intend to help connect Vitastem with the massive amount of consumer search demand online via very advanced SEO strategies, amongst other ongoing digital brand awareness campaigns too,” said Balducci.

ViaDerma President & CEO, Dr. Chris Otiko said, “We are thrilled to bring INTENT SCIENCES in at this time to help us move forward in this new year. We have seen their results with other companies, and we are convinced they will be a perfect fit to help us build the Vitastem brand and greatly increase our revenues for 2023 and beyond.”

ViaDerma announced that they will continue to pursue large orders for purchase and are optimistic they can close them soon.

ViaDerma, Inc.

ViaDerma, Inc., (OTC:VDRM), is a publicly traded specialty pharmaceutical corporation that aims to bring new products to market as well as license its innovative technology to leaders in the pharmaceutical sector in a variety of therapeutic areas. Visit: www.viadermalicensing.com

Under securities laws, any prediction of future performance constitutes a “forward-looking statements”. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:

Investor Relations

Email:  [email protected]

Phone: 310-734-6111

Follow ViaDerma Twitter: https://twitter.com/viaderma

Follow ViaDerma Facebook: https://www.facebook.com/viadermapharma

Previous post Patriots could target Browns passing game coordinator/WR coach Chad O’Shea
Next post Lucid sold more cars in 2022 that it had anticipated